🚀 VC round data is live in beta, check it out!
Cohance Lifesciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cohance Lifesciences and similar public comparables like Bicara Therapeutics, Nanobiotix, Immatics, Sinopep and more.
Cohance Lifesciences Overview
About Cohance Lifesciences
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
Founded
2018
HQ
Employees
1.2K
Website
Sectors
Financials (LTM)
EV
$1B
Cohance Lifesciences Financials
Cohance Lifesciences reported last 12-month revenue of $244M and EBITDA of $51M.
In the same LTM period, Cohance Lifesciences generated $180M in gross profit, $51M in EBITDA, and $25M in net income.
Revenue (LTM)
Cohance Lifesciences P&L
In the most recent fiscal year, Cohance Lifesciences reported revenue of $306M and EBITDA of $83M.
Cohance Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $244M | XXX | $306M | XXX | XXX | XXX |
| Gross Profit | $180M | XXX | $92M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | $51M | XXX | $83M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $25M | XXX | $54M | XXX | XXX | XXX |
| Net Margin | 10% | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cohance Lifesciences Stock Performance
Cohance Lifesciences has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Cohance Lifesciences' stock price is $3.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -6.6% | XXX | XXX | XXX | $0.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCohance Lifesciences Valuation Multiples
Cohance Lifesciences trades at 6.0x EV/Revenue multiple, and 28.5x EV/EBITDA.
EV / Revenue (LTM)
Cohance Lifesciences Financial Valuation Multiples
As of April 14, 2026, Cohance Lifesciences has market cap of $1B and EV of $1B.
Equity research analysts estimate Cohance Lifesciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cohance Lifesciences has a P/E ratio of 57.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 6.0x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 28.5x | XXX | 17.6x | XXX | XXX | XXX |
| EV/EBIT | 37.0x | XXX | 21.6x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | 15.9x | XXX | XXX | XXX |
| P/E | 57.8x | XXX | 26.8x | XXX | XXX | XXX |
| EV/FCF | 76.7x | XXX | 103.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cohance Lifesciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cohance Lifesciences Margins & Growth Rates
Cohance Lifesciences' revenue in the last 12 month grew by 15%.
Cohance Lifesciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.0M for the same period.
Cohance Lifesciences' rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cohance Lifesciences' rule of X is 89% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cohance Lifesciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | (21%) | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | (39%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 89% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cohance Lifesciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Bicara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanobiotix | XXX | XXX | XXX | XXX | XXX | XXX |
| Immatics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinopep | XXX | XXX | XXX | XXX | XXX | XXX |
| Ab&B Bio-Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cohance Lifesciences M&A Activity
Cohance Lifesciences acquired XXX companies to date.
Last acquisition by Cohance Lifesciences was on XXXXXXXX, XXXXX. Cohance Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cohance Lifesciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCohance Lifesciences Investment Activity
Cohance Lifesciences invested in XXX companies to date.
Cohance Lifesciences made its latest investment on XXXXXXXX, XXXXX. Cohance Lifesciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cohance Lifesciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cohance Lifesciences
| When was Cohance Lifesciences founded? | Cohance Lifesciences was founded in 2018. |
| Where is Cohance Lifesciences headquartered? | Cohance Lifesciences is headquartered in India. |
| How many employees does Cohance Lifesciences have? | As of today, Cohance Lifesciences has over 1K employees. |
| Is Cohance Lifesciences publicly listed? | Yes, Cohance Lifesciences is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Cohance Lifesciences? | Cohance Lifesciences trades under COHANCE ticker. |
| When did Cohance Lifesciences go public? | Cohance Lifesciences went public in 2020. |
| Who are competitors of Cohance Lifesciences? | Cohance Lifesciences main competitors are Bicara Therapeutics, Nanobiotix, Immatics, Sinopep. |
| What is the current market cap of Cohance Lifesciences? | Cohance Lifesciences' current market cap is $1B. |
| What is the current revenue of Cohance Lifesciences? | Cohance Lifesciences' last 12 months revenue is $244M. |
| What is the current revenue growth of Cohance Lifesciences? | Cohance Lifesciences revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Cohance Lifesciences? | Current revenue multiple of Cohance Lifesciences is 6.0x. |
| Is Cohance Lifesciences profitable? | Yes, Cohance Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cohance Lifesciences? | Cohance Lifesciences' last 12 months EBITDA is $51M. |
| What is Cohance Lifesciences' EBITDA margin? | Cohance Lifesciences' last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Cohance Lifesciences? | Current EBITDA multiple of Cohance Lifesciences is 28.5x. |
| What is the current FCF of Cohance Lifesciences? | Cohance Lifesciences' last 12 months FCF is $19M. |
| What is Cohance Lifesciences' FCF margin? | Cohance Lifesciences' last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Cohance Lifesciences? | Current FCF multiple of Cohance Lifesciences is 76.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.